Results 141 to 150 of about 127,263 (196)

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. [PDF]

Cureus
Graczyk NA, Bisschops J.
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives. [PDF]

Int J Mol Sci
Gong X, Örge FH.
europepmc   +1 more source

Opposite kinetics of L-leucine and L-phenylalanine induced insulin release studies with the perfused rat pancreas [PDF]

, 1972
Landgraf, R., Landgraf-Leurs, M. M. C., Schwarz, K., Scriba, Peter Christian   +3 more
core  

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. [PDF]

J Clin Invest
Wong CK, Drucker DJ.
europepmc   +1 more source

The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review. [PDF]

Rev Cardiovasc Med
Gala D, Botros F, Makaryus AN.
europepmc   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review. [PDF]

Ther Adv Psychopharmacol
Lee S, Yin L, Teopiz KM, Wong S, Han Le G, Xiao N, Stahl S, Valentino K, Ho R, Zhang MC, Greg Rhee T, McIntyre RS.   +11 more
europepmc   +1 more source

Delayed-Onset Amiodarone Induced Thyrotoxicosis After Glucagon-Like Peptide-1 Agonist-Related Weight Loss. [PDF]

JCEM Case Rep
Black ML, Coyle CG, Bernet VJ, McLeod CJ, Chindris AM.   +4 more
europepmc   +1 more source